IP Library Granted Patent US 7,199,131
Granted Patent B2
US 7,199,131 · App. 11/101,369 · Granted Apr 3, 2007

Sulfonamide and sulfamide substituted imidazoquinolines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,199,131
App. No.
11/101,369
Granted
Apr 3, 2007
Kind
B2
Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Claims (3)

1. A method of inducing INF-α biosynthesis in an animal comprising administering an effective amount of the compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide or a pharmaceutically acceptable salt thereof to the animal.

2. A method of treating a viral disease selected from the group consisting of genital warts, common warts, plantar warts, Hepatitis B, Hepatitis C, Herpes Simplex Virus Type I and Type II, molluscum contagiosum, HIV, CMV, VZV, and human papillomavirus in an animal comprising administering a therapeutically effective amount of N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide or a pharmaceutically acceptable salt thereof to the animal.

3. A method of treating a neoplastic disease selected from the group consisting of intraepithelial neoplasia, including cervical intraepithelial neoplasia, neoplasias caused by human papillomavirus, basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma in an animal comprising administering a therapeutically effective amount of N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide or a pharmaceutically acceptable salt thereof to the animal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2011
From: COLEY PHARMACEUTICAL GROUP, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 026167/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2007
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: COLEY PHARMACEUTICAL GROUP, INC.
Reel/Frame 019965/0551 →